Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baylor College of Medicine, Houston
Inhibition of MDM2 proposed as therapeutic strategy for neuroblastoma
December 17th, 2005
Inhibition of MDM2 was proposed as a therapeutic strategy for neuroblastoma. According to recent research from the United States, "MYCN amplification is associated with an exceptionally poor prognosis in neuroblastoma. Furthermore, the crucial effectors of MYCN responsible for this aggressive subset of neuroblastoma await characterization." "A critical negative regulator of the p53 tumor suppressor, MDM2, has been recently characterized in neuroblastoma cell lines as a transcriptional target of MYCN. Targeted inhibition of MYCN results in reduced MDM2 expression levels, with concomitant stabilization of p53 and stimulation of apoptosis in MYCN...
Source: Mental Health Law Weekly (2005-12-17)
|
